Doxazosin

Generic Name
Doxazosin
Brand Names
Cardura
Drug Type
Small Molecule
Chemical Formula
C23H25N5O5
CAS Number
74191-85-8
Unique Ingredient Identifier
NW1291F1W8
Background

Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 199...

Indication

Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension. Off-label uses of doxazosin include the treatment of pediatric hype...

Associated Conditions
Benign Prostatic Hyperplasia (BPH), Hypertension, Ureteric calculus
Associated Therapies
-

Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin

First Posted Date
2022-05-04
Last Posted Date
2022-05-04
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
189
Registration Number
NCT05360953
Locations
🇩🇪

Berlin St. Hedwig, Berlin, Germany

🇩🇪

Zentralinstitut für Seelische Gesundheit Mannheim, Mannheim, Germany

🇩🇪

Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Psychiatrie und Psychotherapie, Berlin, Germany

and more 1 locations

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2019-10-23
Last Posted Date
2024-08-06
Lead Sponsor
Brown University
Target Recruit Count
184
Registration Number
NCT04135846
Locations
🇺🇸

Brown University, Providence, Rhode Island, United States

Preoperative Alpha Blockade for Pheochromocytoma

First Posted Date
2017-06-05
Last Posted Date
2023-11-20
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
39
Registration Number
NCT03176693
Locations
🇺🇸

University of California, Los angeles, Los Angeles, California, United States

Testing Doxazosin to Treat Stress Mechanisms in Alcoholism

Phase 2
Completed
Conditions
Interventions
First Posted Date
2016-12-12
Last Posted Date
2021-03-18
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
61
Registration Number
NCT02989493
Locations
🇺🇸

University of Wisconsin, Madison, Wisconsin, United States

Doxazosin and Ramipril in Hypertension

Phase 4
Completed
Conditions
Interventions
First Posted Date
2016-09-15
Last Posted Date
2016-09-15
Lead Sponsor
Karolinska Institutet
Target Recruit Count
71
Registration Number
NCT02901977
Locations
🇸🇪

Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory, Stockholm, Sweden

DOX as a Potential Treatment for Methamphetamine Dependence

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-05-27
Last Posted Date
2016-09-29
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
11
Registration Number
NCT02785393
Locations
🇺🇸

Michael Debakey VA Medical Center, Houston, Texas, United States

The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients

Phase 2
Conditions
Interventions
First Posted Date
2015-09-30
Last Posted Date
2016-07-28
Lead Sponsor
First Affiliated Hospital of Harbin Medical University
Target Recruit Count
30
Registration Number
NCT02563405
Locations
🇨🇳

uric acid test and 24-hour ambulatory BP monitoring, Harbin, Heilongjiang, China

Complementary Combination Therapy for Cocaine Dependence

First Posted Date
2015-09-02
Last Posted Date
2022-04-26
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
45
Registration Number
NCT02538744
Locations
🇺🇸

Michael Debakey VA Medical Center, Houston, Texas, United States

CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

First Posted Date
2015-07-16
Last Posted Date
2021-05-13
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
144
Registration Number
NCT02500602
Locations
🇺🇸

Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States

Optimum Treatment for Drug-Resistant Hypertension

First Posted Date
2015-02-23
Last Posted Date
2015-07-03
Lead Sponsor
University of Cambridge
Target Recruit Count
348
Registration Number
NCT02369081
Locations
🇬🇧

University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

🇬🇧

University of Birmingham, Birmingham, United Kingdom

🇬🇧

University of Cambridge - Addenbrookes Hospital, Cambridge, United Kingdom

and more 13 locations
© Copyright 2024. All Rights Reserved by MedPath